PsychoGenics Inc. has launched eCube, a novel pharmaco-electroencephalography (pharmacoEEG) platform to support phenotypic drug discovery. The platform measures drug-induced changes to EEG spectra data and utilises machine learning classifiers trained on reference drugs to predict the efficacy of novel compounds at the drug class and subclass levels. The platform can deliver translational biomarkers to assess central nervous system activity and can identify CNS penetrant compounds and predict their therapeutic applications for neuropsychiatric disorders.
What You Should Know:
– PsychoGenics Inc., a provider of AI-enabled phenotypic drug discovery and preclinical CRO services launches eCube®, a novel pharmaco-electroencephalography (“pharmacoEEG”) platform.
The platform supports phenotypic drug discovery, which unlike traditional target-based drug discovery, can identify novel treatments with multiple targets.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
How eCube Works
eCube measures drug-induced changes to EEG spectra data and utilizes machine learning classifiers trained on reference drugs to predict the efficacy of novel compounds at the drug class (primary therapeutic indication) and subclass (primary mechanism of action) levels. In addition to predicting therapeutic applications for novel compounds, eCube can deliver translational biomarkers, providing an objective way to assess CNS activity, which is particularly important for compounds with unknown or complex mechanisms of action.
Similar to the Company’s AI-enabled, behavior-based platform, SmartCube®, eCube harnesses machine learning to identify CNS penetrant compounds and predict their therapeutic applications for neuropsychiatric disorders by comparing their EEG profiles to an extensive pharmacoEEG database comprised of hundreds of doses of CNS-active reference drugs.
Source: HitConsultant